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Abstract
Introduction: Previously generated serum and plasma proteomic profiles were exam-
ined amongadultswithDown syndrome (DS) to determinewhether these profiles could
discriminate those with mild cognitive impairment (MCI-DS) and Alzheimer’s disease
(DS-AD) from those cognitively stable (CS).
Methods:Data were analyzed on n = 305 (n = 225 CS; n = 44 MCI-DS; n = 36 DS-AD)
enrolled in the Alzheimer’s Biomarker Consortium–Down Syndrome (ABC–DS).
Results:DistinguishingMCI-DS fromCS, the serum profile produced an area under the
curve (AUC) = 0.95 (sensitivity [SN] = 0.91; specificity [SP] = 0.99) and an AUC = 0.98
(SN= 0.96; SP= 0.97) for plasmawhen using an optimized cut-off score. Distinguishing
DS-AD fromCS, the serumprofile producedanAUC=0.93 (SN=0.81; SP=0.99) andan
AUC=0.95 (SN=0.86; SP=1.0) for plasmawhenusing anoptimized cut-off score. AUC
remained unchanged to slightly improved when age and sex were included. Eotaxin3,
interleukin (IL)-10, C-reactive protein, IL-18, serum amyloid A , and FABP3 correlated
fractions at r2 > = 0.90.
Discussion: Proteomic profiles showed excellent detection accuracy for MCI-DS and
DS-AD.
1 INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenerative
disease impacting nearly 5.8 million Americans (https://www.alz.org/
alzheimers-dementia/facts-figures). Although the risk forAD increases
with age, some populations face a disproportionate burden when it
comes to development of AD neuropathology. One of the highest at-
risk groups is adults with Down syndrome (DS) due, at least in part, to
the overexpression of the amyloid precursor protein (APP) located on
chromosome 21.1 Although the age at onset of AD varies widely, from
under 40 years to over 70, in this population, recent estimates show
that>70%of adults withDS over the age of 60meet diagnostic criteria
for AD.2
Diagnosing a neurodegenerative cognitive disorder in adults with
DS poses considerable challenges due to a wide range of premorbid
intellectual and functional abilities.3 Therefore, use of alternativemea-
sures such as biomarkers derived from neuroimaging, cerebrospinal
fluid (CSF), or blood have all been increasingly explored in the pop-
ulation with DS as well as in the broader AD population. The use of
blood-based biomarkers as both individual and combined indicators of
disease presence have gained considerable support for application in
adults with DS due to the need for less invasive and burdensome (ie,
time, cost) screening tools that can be used both in clinical practice and
clinical trials.
Because adults with DS exhibit increased amounts of amyloid beta
(A𝛽) associated with the overexpression of APP, the majority of stud-
ies examining risk of AD have focused on A𝛽 . In plasma, an initial
increase in A𝛽 1-42 was found to be associated with increased risk
for dementia among adults with DS4; follow-up work indicated that
when compared to the lowest quartile, those with middle to highest
quartiles were more than twice as likely to develop AD, with the high-
est quartile also linked to increased mortality.5 More recent work that
evaluated A𝛽 as both individual peptides (A𝛽1-42 and A𝛽1-40) and in
combination (A𝛽1-42/A𝛽1-40) identified that an increase in A𝛽1-40
along with a decrease in A𝛽1-42 and the A𝛽1-42/A𝛽1-40 ratio was
associatedwith increased riskof developmentofAD inadultswithDS.6
Fortea et al. similarly examined A𝛽 peptides in both CSF and plasma
as well as additional biomarkers associated with neurodegeneration
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including neurofilament light (NfL).7 Their findings revealed that
plasma NfL was the only blood-based biomarker associated with pro-
dromal ADandADdementia in adultswithDSwhereas plasmaA𝛽 pep-
tides were not found to be associated with clinical status.7
Among adults with DS and AD, additional individual plasma
biomarkers have been evaluated including a number of inflammatory
cytokines. Iulita et al.8 identified elevations in tumor necrosis factor
alpha (TNF-𝛼), interferon gamma (IFN-y), interleukin 6 (IL-6), and IL-10
along with several additional proteins in adults with DS and AD when
compared with healthy controls without DS.8 In the same study, IL-8
was also found to be significantly elevated among adults with DS and
AD compared to those with DS but without evidence of dementia.8
Recent work from our group identified an increase in several of the
same plasma inflammatory proteins (ie, IL-6, C-reactive protein [CRP],
IL-10, IL-18, thymus and activation regulated chemokine [TARC], TNF-
𝛼, and thrombopoietin [TPO]) in a proteomic profile for prevalent AD
in adults with DS with 89% accuracy.9 Similar inflammatory plasma
biomarkers were also found to drive the proteomic profile for preva-
lent mild cognitive impairment (MCI) in adults with DS (MCI-DS) with
92% accuracy.9
Despite a number of studies examining the link between plasma
blood-based biomarkers of AD among adults with DS, fewer stud-
ies have been conducted in serum. This is in contrast to the general
AD population, in which a serum proteomic profile has been success-
fully validated across multiple cohorts,10 assays, species, and tissue.11
This same serum derived proteomic profile has also been successful in
discriminating AD from other neurodegenerative conditions.12,13 One
study that examined neuronal exomes in adults with DS found no sig-
nificant difference between serum and plasma A𝛽1-42, T-T181-tau,
and P-S396-tau levels.14 However, the authors found significant ele-
vations in each of these markers among adults with DS when com-
pared to neurotypical age-matched controls.14 This study is among the
first to show the utility of serumblood-based biomarkers among adults
with DS.
In our prior work that examined proteomic biomarkers in a sam-
ple of older adults with and without AD in the general population,
we found that several biomarkers were poorly associated across
blood fractions.10 To our knowledge, no study to date has exam-
ined the correlation of the same biomarkers spanning serum and
plasma among adults with DS. Here we aimed to: (1) apply our pre-
viously generated serum and plasma proteomic profiles for AD and
MCI in the general population to adults with DS and (2) examine




The study sample comprises n = 305 (n = 225 cognitively stable
[CS]; n = 44 MCI-DS; n = 36 DS-AD) adult participants with DS
enrolled in the Alzheimer’s Biomarker Consortium–Down Syndrome
Research in Context
1. Systematic review: Literature was identified and
reviewed through PubMed. A growing body of litera-
ture supports the use of blood-based biomarkers as a
means of detecting mild cognitive impairment (MCI) and
Alzheimer’s disease (AD) in the neurotypical population.
Most of the research examining blood biomarkers among
adults with Down syndrome (DS) in the context of neu-
rodegenerative cognitive disorders has been conducted
in plasma. Only one study examined the utility of blood
biomarkers in serum. No work to date has applied pre-
viously generated blood-based proteomic profiles for
detecting MCI and AD in the neurotypical population to
adultswithDS to examine the application of such profiles.
Additionally, no work has examined the correlation of
the same biomarker proteins across serum and plasma
among adults with DS.
2. Interpretation: Our findings revealed that previously
established proteomic profiles produced excellent detec-
tion accuracy when tasked with distinguishing MCI-DS
and DS-AD from those with DS who are cognitively sta-
ble (CS). Detection accuracy based on an optimized cut-
off score reached an area under the curve (AUC) ranging
from 95% to 98% for serum and plasma proteomic pro-
files for MCI-DS when distinguishing from those with CS.
The same serum and plasma proteomic profiles exhibited
similar AUCs ranging from 93% to 95% in distinguishing
DS-AD from CS, again when an optimized cut-off score
was applied. Inclusion of sex and age improved almost
all non-optimized proteomic predictive models. Although
most biomarkers were highly correlated across fraction,
several correlated r2 > 90 and included Eotaxin3, inter-
leukin (IL)-10, C-reactive protein, IL-18, serum amyloid A,
and fatty acid binding protein 3.
3. Future directions: This work was able to validate a pre-
viously generated serum and plasma proteomic profile
from the neurotypical AD population among adults with
DS. Findings from this study revealed the utility of serum
blood-based biomarkers, which have only been looked at
in a limited capacity among adults with DS. Future work
should expand on the current findings to evaluate cross-
over between serum and plasma biomarkers that, if com-
bined, could potentially increase diagnostic accuracy.
(ABC–DS; https://www.nia.nih.gov/research/abc-ds). The ABC–DS
is a prospective clinical cohort study of biomarkers associated with
AD among adults with DS. ABC–DS sites include University of Pitts-
burgh, University of Wisconsin Madison, University of Cambridge,
WashingtonUniversity in St. Louis, ColumbiaUniversity IrvingMedical
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TABLE 1 Demographic characteristics of participants
Characteristic CS MCI-DS DS-AD
N 225 44 36
Age 42.4± 9.1 52.9± 6.9* 54.3± 6.2*
Sex N (%)
Male 127 (52.5) 35 (68.6) 21(48.8)
Female 115 (47.5) 16 (31.4)* 22 (51.2)
Level of function N (%)
Mild/moderate 228 (94.2) 37 (88.1) 37 (88.1)
Severe/profound 9 (3.7) 5 (11.9) 5 (11.6)
Ethnicity N (%)
White 234 (97.1) 47 (92.2)* 40 (93.0)
Non-white 7 (2.9) 4 (7.8) 3 (7.0)
APOE ɛ4 allele N (%) 45 (21.1) 15 (34.1) 14 (35.0)
Note: Significance P-value<.05*,<.001**
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CS, cogni-
tively stable; DS, Down syndrome;MCI, mild cognitive impairment
Center, Johns Hopkins University Bloomberg School of Public Health,
University of California, Harvard/Massachusetts General Hospital,
Hackensack University Medical Center, The New York State Institute
for Basic Research in Developmental Disabilities, Georgetown Univer-
sity, and University of North Texas Health Science Center. The overall
goals of ABC–DS are to: (1) identify sensitive neuropsychological
measures of cognitive decline, imaging, blood-based, and genetic
biomarkers associated with transition from normal aging to MCI and
AD among adults with DS; (2) identify critical factors that link cerebral
amyloid deposition to neurodegeneration and ultimately dementia;
(3) understand the relationships between biomarkers and pathways
implicated in AD pathogenesis in preparation for clinical trials for AD
in the DS population; and (4) provide rapid public access to all data,
without embargo, and access to the biological samples by qualified
scientific investigators. Study visits include a baseline visit, followed
by subsequent assessments at 16 and 32months. Data from this study
come from blood collected at the ABC–DS baseline visit. Demographic
characteristics of the cohort are presented in Table 1. The cohort
comprises cognitively stable adults with DS and adults with and
without prevalent MCI-DS and AD. All ABC–DS sites operate under
institutional review board approved protocols and informed consent
and or assent was obtained for all participants.
2.2 Clinical assessment
Assessments included evaluations of cognition and functional abilities,
behavioral and/or psychiatric conditions, and health status. Cognitive
function was evaluated with a test battery designed for use with indi-
viduals with DS varyingwidely in their pre-morbid levels of intellectual
functioning. Structured interviews were conducted with caregivers to
collect information on changes in cognition, day-to-day functioning,
adaptive behavior, andmedical status.
2.3 Classification of dementia
The classification of dementia status, dementia subtype, and age at
onset was determined during clinical consensus conferences at which
information from available sources including medical, clinical, and cog-
nitive testing were reviewed. Participants were classified into three
groups, generally consistent with the recommendations of the AAMR-
IASSIDWorking Group for the Establishment of Criteria for the Diag-
nosis of Dementia in Individuals with Developmental Disability.15,16
Participants were classified as CS if they were without cognitive or
functional decline. Participantswere classified as havingMCI-DS if they
demonstrated somecognitive and/or functional decline over and above
what would be expected with aging per se based on performance on
neuropsychological assessment as well as documented by informant
report, but not severe enough to indicate the presence of demen-
tia. Participants were categorized as having dementia (DS-AD) if there
was evidence of substantial progressive declines in cognitive function-
ing and daily living skills. An unable to determine category was used
to indicate that declines were observed but that symptoms could be
caused by life circumstance (eg, staff changes) or conditions unrelated
to AD (eg, severe sensory loss, poorly resolved hip fracture, psychiatric
diagnosis).
2.4 Apolipoprotein E (APOE)
DNA samples were genotyped for two APOE single-nucleotide poly-
morphisms (SNPs) (rs429358 and rs7412) with the KASP genotyping
system by LGC Genomics. Genotype data for these two SNPs were
used to define APOE 𝜀2, 𝜀3, and 𝜀4 alleles. For analysis, we classified
individuals with at least one copy ofAPOE 𝜀4 allele to beAPOE 𝜀4 carri-
ers. APOE carrier status was included in the description of the sample
but was otherwise omitted from follow-up analyses conducted in this
study.
2.5 Assays
Plasma and serum samples were analyzed at the Institute for Transla-
tional Research (ITR) Biomarker Core. Automation of the proteomic
assay preparation was conducted using a customized Hamilton
Robotics StarPlus system. This automated liquid handling workstation
substantially improves reliability of assay preparation, which reduces
error and coefficients of variation (CVs) and provides increased
quality assurance/quality control (QA/QC) monitoring. Any re-aliquot
needs were conducted via the Hamilton easyBlood robotic system.
Commercially available proteomic assays were obtained from Meso
Scale Discovery (MSD; http://www.mesoscale.com) and assayed
using electrochemiluminescence (ECL) per our previously published
methods.11,17 The ECL platform has been used extensively to assay
biomarkers associated with a range of human diseases including
AD.18,19-21 ECL technology uses labels that emit light when elec-
tronically stimulated, which improves the sensitivity of detection
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of many analytes at very low concentrations. ECL measures have
well-established properties of being more sensitive and requiring
less volume than conventional enzyme-linked immunosorbent assays
(ELISAs),19 the gold standard for most assays. Although a number of
platforms are available for assays including those considered to be
more sensitive (ie, SIMOA),22 priorwork conducted in the neurotypical
AD population has demonstrated how successful ECL technology can
bewhen applied to this targeted proteomic panel with CVs< 10%.17,23
Our lab maintains a database of more than n > 2000 samples con-
ducted in duplicate on the sameMSDplates and equipment referenced
in this study. Our average CVs remain < 10% for all assays with > 60%
having CVs less than or equal to 6%. Regarding quality control of the
samples, five pooled plasma and five serum controls were included
on each plate layout, which contained a similar distribution of age for
DS samples and sibling controls. All determinations were conducted
in singlicate. A total of 500 𝜇L of plasma and serum were used to
assay the following markers: fatty acid binding protein 3 (FABP3), beta
2 microglobulin (B2M), pancreatic polypeptide (PPY), CRP, TPO, 𝛼2
macroglobulin (A2M), exotaxin 3, TNF-𝛼, tenascin C, IL-5, IL-6, IL-7,
IL-10, IL-18, I-309, factorVII, soluble intercellular adhesionmolecule-1
(sICAM-1), circulating vascular cell adhesion molecule-1 (sVCAM-1),
TARC, and serum amyloid A (SAA). Table S1 in supporting information
provides the CVs, lower limit of detection (LLOD). and highest level of
detection (HLOD) for each assay separated by fraction. CV was deter-
mined by finding the standard deviation/mean × 100 for both fractions
as well as for each biomarker. LLOD for each analyte is determined
at the concentration 2.5 standard deviations above the background
measurement. HLOD is functionally determined from the performance
of each assay. HLOD is usually set where immuno-detection is still
linear and has not reached a plateau (ie, top standard concentration).
2.6 Statistical analyses
Statistical analyses were conducted using the R (V 3.3.3) statistical
software (R Development Core Team, 2009). Differences in demo-
graphic characteristics betweendiagnostic groupswere determinedby
Fisher’s exact test and Mann Whitney U test for categorical variables
(sex) and continuous variables (age and level of premorbid intellectual
functioning, as indicatedbyparticipants’ baseline cognitive assessment
or clinical records). Support vector machine (SVM) analysis was used
with blood-biomarker prediction models. SVM is a method that per-
forms classification tasks by constructing hyperplanes in amultidimen-
sional space to separate cases of different class labels. The samples
from the different groups were randomly distributed over the analyt-
ical runs. Because one biomarker (TPO) was shown to have a relatively
high CV for plasma compared to all other proteins, SVM analyses were
run both with and without this protein. Diagnostic accuracy was cal-
culated using blood-based biomarkers alone and in combination with
demographic characteristics (ie, age and sex) using receiver operating
characteristic (ROC) curves. SVM analyses were run with a five-fold
cross-validation. The optimized cut-off score is defined as a threshold
to maximize the sum of sensitivity and specificity subject to reaching
clinically acceptable levels. Correlations between plasma and serum
proteomic markers were conducted using Pearson correlation coeffi-
cients.
3 RESULTS
When compared to CS participants, those with MCI-DS were signifi-
cantly older (P= .002), of white ethnicity (P= .030), andmale (P= .035)
but did not differ in the distribution of level of intellectual function-
ing (Table 1). Similarly, participantswithDS-ADwere significantly older
(P = .001) compared to those participants who were CS (Table 1).
Although there was a trend toward significance, APOE ɛ4 status was
comparable in CS andMCI-DS and in CS andDS-AD participants.
When distinguishing participants with MCI-DS from those who
were CS, the serum biomarkers alone produced an area under the
curve (AUC) of 95% (sensitivity [SN] = 0.023; specificity [SP] = 1.00).
The range of accuracy for the five cross-validations is 79.6 to 87.0
with the average accuracy of 83.6. The inclusion of age and sex along
with the serum biomarkers improved the AUC to 99% (SN = 0.45;
SP = 1.00). The range of accuracy of the five cross-validations is 79.6
to 88.7 with the average accuracy of 83.6. Use of an optimized cut-
off score of –0.977 for the serum biomarkers alone increased sensitiv-
ity to 0.91 while AUC and specificity remained relatively unchanged
(AUC = 95%; SP = 0.99). Applying the same model but using plasma
biomarkers alone produced an AUC of 98% (SN= 0.07; SP= 1.00). The
range of accuracy for the five cross-validations is 79.2 to 90.7 with the
average accuracy of 83.6. The addition of age and sex did not signifi-
cantly impact the model as AUC, sensitivity, and specificity remained
relatively unchanged (AUC = 0.97; SN = 0.05; SP = 1.00). The range of
accuracy for the five cross-validations is 72.2 to 90.7 with an average
accuracy of 83.3. Again, use of an optimized cut-off score of –0.98 for
the plasma biomarkers alone increased sensitivity to 0.96 while AUC
and specificity remained stable (AUC= 98%; SP= 0.98; Figure 1).
When distinguishing among participants with DS-AD from those
who were CS, the serum biomarkers alone produced an AUC of 93%
(SN = 0.08; SP = 1.00). The range of accuracy for the five cross-
validations is 82.7 to 92.3 with an average accuracy of 86.2. The addi-
tion of age and sex increased the AUC to 98% (SN = 0.17; SP = 1.00).
The range of accuracy for the five cross-validations is 75.5 to 96.2
with an average accuracy of 86.2. Use of an optimized cut-off score
of –0.905 for serum biomarkers alone increased sensitivity to 0.81
while AUC and specificity remained relatively unchanged (AUC= 93%;
SP = 0.99). The plasma proteomic profile alone produced an AUC of
95% (SN = 0.08; SP = 1.00). The range of accuracy for the five cross-
validations is 82.7 to 90.4 with an average accuracy of 86.2. The addi-
tion of age and sex increased the AUC to 98% (SN = 0.19; SP = 1.00).
The range of accuracy for the five cross-validations is 80.8 to 906 with
an average accuracy of 85.8. Use of an optimized cut-off score of –0.89
for plasma biomarkers alone increased sensitivity to 0.86 while AUC
and specificity remained stable (AUC= 0.95; SP= 1.00; Figure 2).
When examining the SVM variable importance plots for predict-
ing MCI-DS, six of the top ten biomarkers were elevated across blood
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F IGURE 1 Receiver operating characteristic (ROC) curves and variable importance plots for serum and plasma proteomic profile for detecting
mild cognitive impairment-Down syndrome (MCI-DS). Note: MCI-DS, fatty acid binding protein (FABP3), beta 2microglobulin (B2M), pancreatic
polypeptide (PPY), C-reactive protein (CRP), soluble intercellular adhesionmolecule-1 (sICAM-1), circulating vascular cell adhesionmolecule-1
(sVCAM-1), tumor necrosis factor-alpha (TNF-𝛼), interleukin (IL)-5, IL-6, interleukin IL-7, IL-10, IL-18, factor VII (Factor7), thymus and activation
regulated chemokine (TARC), and serum amyloid A (SAA)
fractions and included IL-10, CRP, Factor7, IL-6, FABP3, and B2M.
For predicting DS-AD, six of the top ten biomarkers were elevated
across blood fractions and included IL-10, PPY, Factor7, IL-18, IL-6, and
Eotaxin3 (Figures 1 and 2).
Of note, TPO was excluded from initial SVM models due to the
unusually high assay performance parameters for plasma (CV > 40%;
Table S1). Because assay performance parameters are derived from
pooled DS sibling control cases, the SVMmodels were re-run with the
inclusion of TPO for both MCI-DS and DS-AD to see how this pro-
tein would (if at all) impact the proteomic profiles. Results revealed
that when TPO was included, it was the top biomarker (as measured
by the variable importance plot) for both the serum and plasma pro-
teomic profiles forMCI-DS. TPOwas also among the top two biomark-
ers for the DS-AD proteomic profiles again spanning across fractions.
ForMCI-DS, therewas no change to the testing set for serumbiomark-
ers once TPO was removed, while for plasma biomarkers, when TPO
was removed, the specificity for the testing set decreased; however,
this changewasnot statistically significant (P-value= .176). ForDS-AD,
the sensitivity decreased for the testing setwhile the specificity for the
testing set increased for the serum based proteomic profile; however,
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F IGURE 2 Receiver operating characteristic (ROC) curves and variable importance plots for serum and plasma proteomic profile for detecting
Down syndrome-Alzheimer’s disease (DS-AD). Note: fatty acid binding protein (FABP3), beta 2microglobulin (B2M), pancreatic polypeptide (PPY),
C-reactive protein (CRP), soluble intercellular adhesionmolecule-1 (sICAM-1), circulating vascular cell adhesionmolecule-1 (sVCAM-1), tumor
necrosis factor-alpha (TNF-𝛼), interleukin (IL)-5, IL-6, IL-7, IL-10, IL-18, factor VII (Factor7), thymus and activation regulated chemokine (TARC),
and serum amyloid A (SAA)
this change was again not statistically significant (P-value = .859). For
the plasma based proteomic profile for DS-AD, the testing set slightly
decreased after removing TPO; however, the change was not statisti-
cally significant (P-value= .119).
Because the majority of work examining biomarkers related to
disease status among adults with DS has been conducted in plasma, it
was important to explore the correlation between biomarkers across
fraction (serum and plasma). Those proteins with a high correlation
reflect biomarkers that are able to be well detected within a dis-
ease status (MCI-DS, DS-AD) despite differences between fractions
including clotting factors and so on. Findings revealed that the cor-
relations of all proteins were statistically significant between serum
and plasma (P < .001; Tables 2 and 3) with the majority of markers
correlated at a level of 0.7 or higher. However, when considering the
biological meaningfulness of the correlations, only Eotaxin3, IL-6, IL-
10, CRP, IL-18, SAA, and FABP3 correlated at a level to suggest at least
an 80% of shared variance or greater (ie, r2 > = 0.90). Interestingly,
many of the markers that correlated most highly across both blood
fractions were also ranked very highly in the proteomic profiles for
detecting DS-MCI andDS-AD across both blood fractions.
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Abbreviations: A2M, alpha 2 macroglobulin; B2M, beta 2 microglobulin;
CRP, c-reactive protein; Factor7, factor VII; FABP3, fatty acid binding pro-
tein; IL-10, interleukin-10; IL-18, interleukin-18; IL-5, interleukin-5; IL-6,
interleukin-6; IL-7, interleukin-7; PPY, pancreatic polypeptide; SAA, serum
amyloid A; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-
1, circulating vascular cell adhesion molecule-1; TARC, thymus and acti-
vation regulated chemokine; TNF-𝛼, tumor necrosis factor-alpha; TPO,
thrombopoietin
4 DISCUSSION
This study was the first to apply a specific panel of proteomic markers
previously selected and validated in the neurotypical AD population,
in adults with DS. The results reveal that proteomic profiles derived
from both serum and plasma produce similar levels of accuracy across
disease state (MCI-DS, DS-AD). The addition of age and sex increased
accuracy for all proteomic profiles with the exception of the plasma
proteomic profile forMCI-DS,which remainedelevatedwith anAUCof
98%. Use of an optimized cut-off score improvedmost predictivemod-
els by increasing sensitivity. The detection accuracy from the derived
proteomic profiles for bothMCI-DS and DS-AD based on an optimized
cut-off scoremirrored that observed in theneurotypicalADpopulation
showing its utility for application in the DS population. Our findings
reveal that although many of the same biomarkers significantly impact
the proteomic profiles across blood fractions, for most cases, the vari-
able importance plots were distinct with only a few exceptions.
One example includes the MCI-DS serum and plasma proteomic
profiles, which comprised the same top biomarker (IL-10) on the
variable importance plot. Of note, the remaining combination of
biomarkers comprising ranks 3 to 10 differed by fraction for MCI-DS.
When TPOwas included in themodel, it was found to play a significant
role in both the MCI-DS and DS-AD proteomic profiles spanning frac-
tions. TPO is a knownglycoprotein hormone that aids in the production
of platelets24,25 and in DS, TPO has been almost exclusively studied
among pediatric cases due to high level of thrombocytopenia.26-28
Although TPO exhibited an unexpectedly high CV for plasma (and
was initially excluded from derived protoemic profiles), the inclusion
of TPO did not significantly change the detection accuracy of the
proteomic profiles despite its prominence within the models. This
suggests that TPO may play an important role among individuals
with DS who also experience MCI or AD and should be explored
further.
When looking more broadly at the proteomic profile for MCI-DS,
the serum proteomic profile was found to be driven by inflamma-
tory based proteins such as IL-10, CRP, and IL-6. While the plasma
proteomic profile for MCI-DS showed similar elevations in inflamma-
tory based proteins (IL-10, B2M, TARC, IL-6), the profile also included
other biomarkers such as those related to endocrine function (PPY).
The same inflammatory driven proteomic profile was found for DS-
AD (B2M, TNF-𝛼, IL-5, IL-10, CRP, IL-18, IL-6) again spanning frac-
tions similar to MCI-DS. This finding reflects that observed among
non-Hispanic whites in the neurotypical AD population who also
present with a similar inflammatory based proteomic profile for
AD.10 Among individuals with DS, a number of the same inflamma-
tory biomarkers have been shown to be elevated across the lifespan
suggesting chronic neuroinflammation,29 which corresponds to the
increased predisposition for a number of autoimmune conditions30-33
observed in this population. A meta-analysis conducted primarily
among children with DS revealed elevations in TNF-𝛼, IL-1𝛽 , and IFN-
y,34 while similar elevations in inflammatory cytokines and chemokines
(IL-6, IL-22, and TNF-𝛼) were identified in a different study con-
ducted among adults with DS compared to neurotypical healthy con-
trol adults.35 Despite evidence to support chronic inflammation in this
population, distinct elevations in inflammatory proteins between diag-
nostic categories (MCI-DS and DS-AD) suggests that specific inflam-
matory processes may uniquely contribute to the progression of
cognitive decline among adults with DS. Understanding both the over-
all role inflammation plays in disease progression for adults with DS
will continue to be important as well as the role specific proteins have
across disease status.
One example of why it will be important to examine individual pro-
teins more closely is due to the unique composition of each (serum and
plasma) proteomic profile observed in this study for MCI-DS and DS-
AD.Aside froma few select cases,most proteins held a distinct position
on thevariable importanceplots,whichdifferedby fraction anddisease
status for MCI-DS and DS-AD. One example of this was CRP, which is
a well-known biomarker of inflammation.36 In the MCI-DS serum pro-
teomic profile, CRP was ranked as the third most important protein in
the diagnostic model; however, in the MCI-DS plasma proteomic pro-
file, this same protein was ranked tenth on the variable importance
plot. CRP,whichhasbeenpreviously been linked toAD in theneurotyp-
ical population37 was only among the top 10 biomarkers for the serum
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TABLE 3 Correlation between serum and plasma biomarkers split by diagnostic group
CS MCI-DS DS-AD
R2 P-value R2 P-value R2 P-value
A2M 0.74 <.001 0.81 <.001 0.49 .002
B2M 0.79 <.001 0.71 <.001 0.79 <.001
CRP 0.97 <.001 0.95 <.001 0.96 <.001
Eotaxin3 1.00 <.001 1.00 <.001 0.61 <.001
FABP3 0.95 <.001 0.93 <.001 0.96 <.001
Factor7 0.79 <.001 0.91 <.001 0.75 <.001
I309 0.84 <.001 0.85 <.001 0.86 <.001
IL-10 0.99 <.001 0.87 <.001 0.96 <.001
IL-18 0.97 <.001 0.97 <.001 0.98 <.001
IL-5 0.91 <.001 0.82 <.001 0.70 <.001
IL-6 1.00 <.001 0.46 .002 0.97 <.001
IL-7 0.30 <.001 0.52 <.001 0.34 .04
PPY 0.57 <.001 0.76 .001 0.56 .004
SAA 0.98 <.001 0.93 <.001 0.96 <.001
sICAM1 0.45 <.001 0.29 .063 0.45 .005
sVCAM1 0.52 <.001 0.57 <.001 0.65 <.001
TARC 0.47 <.001 0.58 <.001 0.88 <.001
Tenascin C 0.73 <.001 0.84 <.001 0.78 <.001
TNF-𝛼 0.64 <.001 0.74 <.001 0.43 .009
TPO 0.71 <.001 1.00 <.001 0.94 <.001
Abbreviations: A2M, alpha 2 macroglobulin; AD, Alzheimer’s disease; B2M, beta 2 microglobulin; CRP, c-reactive protein; CS, cognitively stable; DS, Down
syndrome; Factor7, factor VII; FABP3, fatty acid binding protein; IL-10, interleukin-10; IL-18, interleukin-18; IL-5, interleukin-5; IL-6, interleukin-6; IL-7,
interleukin-7; MCI, mild cognitive impairment; PPY, pancreatic polypeptide; SAA, serum amyloid A; sICAM-1, soluble intercellular adhesion molecule-1;
sVCAM-1, circulating vascular cell adhesionmolecule-1; TARC, thymus andactivation regulated chemokine; TNF-𝛼, tumornecrosis factor-alpha; TPO, throm-
bopoietin
protoemic profile for DS-AD and was not found to be among the top
plasma biomarkers.
It will be important for future work to expand on the current
findings to evaluate potential cross-over between serum and plasma
biomarkers that, if combined, could possibly increase diagnostic accu-
racy. Further work, for example, is needed to evaluate how additional
biomarkers linked with neurodegeneration such as NfL, tau, and A𝛽 40
and 42 might impact the proteomic profiles included in this study or
if the proteomic profiles are able to be refined down to only a smaller
number of proteins. One limitation of the study is the relatively small
sample size for those with DS-AD as additional cases could impact
the detection accuracy and variable importance plots. Another limita-
tion to the study is use of DS sibling control cases as a control group,
which produced several instances of high CVs across the proteomic
assays. High CVs likely reflects individual variability among the DS sib-
ling control cases and may not reflect poor performance of the assays
within the DS sample itself. To determine this and help understand
performance of the selected assays among this specific population,
future work will include standardized control samples compared to DS
sibling control samples. The ABC–DS is an ongoing study with contin-
ued recruitment, which will allow for future work to both validate the
same proteomic profiles in a larger sample and to detect phenoconver-
sion fromCS toMCI-DS andDS-AD. This effortwill also help to address
inherent limitations with the diagnostic category ofMCI-DS given that
adults with DS are at increased risk for AD due to higher rates of amy-
loid deposition. This work has implications not only for understanding
DS-ADbutmayprovide important insights relevant to the neurotypical
AD population.
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